Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., . . . Romieu, G. (2010). Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of clinical oncology, 28(20), .
Chicago-Zitierstil (17. Ausg.)Miles, David W., et al. "Phase III Study of Bevacizumab Plus Docetaxel Compared with Placebo Plus Docetaxel for the First-line Treatment of Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer." Journal of Clinical Oncology 28, no. 20 (2010).
MLA-Zitierstil (9. Ausg.)Miles, David W., et al. "Phase III Study of Bevacizumab Plus Docetaxel Compared with Placebo Plus Docetaxel for the First-line Treatment of Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer." Journal of Clinical Oncology, vol. 28, no. 20, 2010.